RIPK1 and colitis: Supporting this, administration of a RIPK1 inhibitor, a kinase-specific inhibition of RIPK1, in a DSS-colitis murine model resulted in improved intestinal barrier homeostasis by reducing epithelial monolayer disruption and maintaining epithelial permeability (Figure 4), suggesting that RIPK1 can contribute to epithelial cell death (56, 83).